Initial Rollout for the ABILIFY MYCITE® System
Our approach for this first-of-its-kind treatment is to collaborate closely with only a select number of health plans and providers.
This limited rollout is purposeful. Having fewer people using the ABILIFY MYCITE System initially means their prescribers, health plans, and Otsuka can focus on learning from patients’ experiences.
During this initial rollout, we will be looking to answer questions such as:
- How does the ABILIFY MYCITE System fit best within the daily lives of those with serious mental illness and their loved ones?
- How do doctors integrate this system into their daily practice?
- How can we improve this system to better serve patients, healthcare providers, and health plans?
Through ongoing feedback from those using the system every day, Otsuka will further enhance the experience for all prospective users of the ABILIFY MYCITE System moving forward.
If you have any questions about the system or ABILIFY MYCITE® (aripiprazole tablets with sensor), your health, or the medicines you take, talk to your doctor. Ask if ABILIFY MYCITE may be an appropriate treatment option for you. During the Initial Rollout, ABILIFY MYCITE will only be covered under a limited number of health plans and will only be available to a limited number of those health plans' member population.
Frequently Asked Initial Rollout Questions
What is ABILIFY MYCITE (aripiprazole tablets with sensor)?
ABILIFY MYCITE is a prescription medicine of an aripiprazole tablet with an Ingestible Event Marker (IEM) sensor inside it used in adults for the:
- Treatment of schizophrenia
Treatment of bipolar I disorder alone or when used with the medicine lithium or valproate for:
- acute (short-term) treatment of manic or mixed episodes
- maintenance treatment
- Treatment of major depressive disorder (MDD) along with other antidepressant medicines
The ABILIFY MYCITE System is intended to track if you have taken your ABILIFY MYCITE. There may be a delay in the detection of the ABILIFY MYCITE tablet and sometimes the detection of the tablet might not happen at all. If the MYCITE® APP does not indicate that you have taken your medicine, do not repeat the dose. It is not known if ABILIFY MYCITE can improve how well you take your aripiprazole (patient compliance) or for changing your dose of aripiprazole. ABILIFY MYCITE is not for use as real-time or emergency monitoring.
Who should not take ABILIFY MYCITE?
Do not take ABILIFY MYCITE if you are allergic to aripiprazole or any of the ingredients in ABILIFY MYCITE. See the MEDICATION GUIDE for a complete list of ingredients in ABILIFY MYCITE.
Is the ABILIFY MYCITE System available to all prospective patients and their doctors?
ABILIFY MYCITE is a first-of-its-kind treatment, so there will be limited product availability at launch. We are rolling out the ABILIFY MYCITE System in close collaboration with only a limited number of health plans and their affiliated doctors through this launch period. The doctors will be able to prescribe to those patients who are appropriate for the ABILIFY MYCITE System.
In August 2018, Otsuka announced that it has signed a Collaboration Agreement to facilitate access to the ABILIFY MYCITE System to select regional provider networks contracted through Magellan Health. The Collaboration Agreement creates the opportunity for physicians and adult patients to gather experience in a real-world setting with the ABILIFY MYCITE System.
How can prospective ABILIFY MYCITE patients find out if they are eligible or have access?
The ABILIFY MYCITE System is available only to a limited number of patients during the initial rollout and we anticipate their participating insurance plans will apprise them of the availability of the product. If you have any questions about ABILIFY MYCITE, your health, or the medicines you take, talk to your doctor.
How long will the Initial Rollout last before the ABILIFY MYCITE System is more broadly available?
A limited initial launch will allow us to gather feedback and further enhance the experience for all prospective users of the ABILIFY MYCITE System. The progress of this initial limited rollout will help us determine timing for a broader product launch.
Please check back here for updates and important news pertaining to the ABILIFY MYCITE System.